Q4 2025 NRX Pharmaceuticals Inc Earnings Call Transcript
Key Points
- NRX Pharmaceuticals Inc (NRXP) anticipates drug approval for KETAFREE over the summer and potential approval for NRX-100 within the year.
- The company has demonstrated EBITDA positive revenue growth through its HOPE Therapeutics clinics.
- NRX Pharmaceuticals Inc (NRXP) has eliminated all convertible debt from its balance sheet and ended the year with $7.8 million in cash.
- The FDA has shown willingness to review real-world evidence for NRX-100, potentially broadening its indication to a larger patient population.
- The company has launched a nationwide expanded access program for NRX-101, with a market estimate for its new indication exceeding $1 billion.
- NRX Pharmaceuticals Inc (NRXP) still faces risks and uncertainties that could affect its forward-looking statements.
- The company is reliant on FDA approval processes, which can be unpredictable and may delay product launches.
- Despite progress, NRX Pharmaceuticals Inc (NRXP) reported a loss from operations of $16.2 million for the year ended December 31, 2025.
- The company’s commercial strategy for KETAFREE is still in development, with reliance on external organizations for hospital sales.
- NRX Pharmaceuticals Inc (NRXP) must continue to manage its cash resources carefully to support operations through 2026.
Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Q4 2025 results conference call. (Operator Instructions) This call is being recorded on Tuesday, March 24, 2026. I would now like to turn the conference over to Michael Abrams, CFO. Please go ahead.
Thank you, Joel. You're welcome, everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under the United States Federal Securities Laws.
These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause results to differ from statements made on this call as contained in our periodic reports filed with the SEC.
The forward-looking statements made during this call speak only of the date hereof, and the company takes no obligation to update or revise
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
